Just before Christmas, the Norwegian company announced that it has received support from Oslo County of 1.950 million NOK.
The funding will support optimization of the synthesis of our two lead compounds, APC148 and APC247. The program will define the optimal characteristics of the substances that will be used for microbiology testing as well as for testing in healthy volunteers in our clinical program.
The R&D project will start first half of 2023 and Adjutec will collaborate closely with Kappa Solutions in Oslo, RISE at Södertälje in Sweden and researchers at the University of Oslo.
Read more: A glimpse of hope in tackling antibiotic resistance – AdjuTec, our NLS Star 2021
“Adjutec continues to attract public funding to support our R&D program. The grant from Oslo County is a recognition of our drug development plans and supports our aim of building healthcare industry in Oslo in collaboration with local providers. It also strengthens the company attractiveness before our next capital raise that is planned first half of 2023 to fund clinical testing of our lead compound APC148,”says Bjørn Klem, CEO, AdjuTec.
Image: Colorized scanning electron micrograph showing carbapenem-resistant klebsiella pneumoniae interacting with a human neutrophil. Photo: NIAID